Display options
Cite
Yang X, Li P, Yang X, et al. TSP-1-1223 A/G Polymorphism as a Potential Predictor of the Recurrence Risk of Bladder Cancer in a Chinese Population. Int J Genomics. 2013;2013:473242doi: 10.1155/2013/473242.
Yang, X., Li, P., Yang, X., Qin, C., Cao, Q., Zhang, Z., Wang, M., Cai, H., Gu, J., Tao, J., Gu, M., Lu, Q., & Yin, C. (2013). TSP-1-1223 A/G Polymorphism as a Potential Predictor of the Recurrence Risk of Bladder Cancer in a Chinese Population. International journal of genomics, 2013473242. https://doi.org/10.1155/2013/473242
Yang, Xiao, et al. "TSP-1-1223 A/G Polymorphism as a Potential Predictor of the Recurrence Risk of Bladder Cancer in a Chinese Population." International journal of genomics vol. 2013 (2013): 473242. doi: https://doi.org/10.1155/2013/473242
Yang X, Li P, Yang X, Qin C, Cao Q, Zhang Z, Wang M, Cai H, Gu J, Tao J, Gu M, Lu Q, Yin C. TSP-1-1223 A/G Polymorphism as a Potential Predictor of the Recurrence Risk of Bladder Cancer in a Chinese Population. Int J Genomics. 2013;2013:473242. doi: 10.1155/2013/473242. Epub 2013 Dec 03. PMID: 24367787; PMCID: PMC3866825.
Copy Download .nbib Format: NLM
Share it on

Int J Genomics. 2013;2013:473242. doi: 10.1155/2013/473242. Epub 2013 Dec 03.

TSP-1-1223 A/G Polymorphism as a Potential Predictor of the Recurrence Risk of Bladder Cancer in a Chinese Population.

International journal of genomics

Xiao Yang, Pengchao Li, Xuejian Yang, Chao Qin, Qiang Cao, Zhengdong Zhang, Meilin Wang, Hongzhou Cai, Jinbao Gu, Jun Tao, Min Gu, Qiang Lu, Changjun Yin

Affiliations

  1. Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
  2. Cancer Center of Nanjing Medical University, Department of Molecular & Genetic Toxicology, Nanjing Medical University, 140 Hanzhong Road, Nanjing 210029, China.

PMID: 24367787 PMCID: PMC3866825 DOI: 10.1155/2013/473242

Abstract

Backgrounds. TSP-1 is a glycoprotein that functions in the biology of bladder cancer. We investigated the relationship between the distribution of TSP-1-1223 A/G polymorphism (rs2169830) and the clinical characteristics of bladder cancer. Materials and Methods. TaqMan assay was performed to determine the genotype of 609 cases and 670 control subjects in a Chinese population. Logistic regression was used to assess the association between the polymorphism and the risk of bladder cancer. Quantitative real-time polymerase chain reaction was performed to determine TSP-1 mRNA expression. Survival curves were generated using the Kaplan-Meier method. Results. No significant differences were detected in the genotype frequencies of healthy control subjects and patients with bladder cancer. By contrast, the time until the first recurrence differed significantly between genotypes (P = 0.017). The expression of TSP-1 mRNA in bladder cancer tissues was lower in patients with an AG genotype than in those with an AA genotype. The lowest expression was observed in patients with a GG genotype. Conclusions. In conclusion, TSP-1-1223 A/G polymorphism may contribute to the recurrence of bladder cancer in Chinese population.

References

  1. Proc Natl Acad Sci U S A. 2001 Oct 23;98(22):12485-90 - PubMed
  2. EMBO J. 1995 Jan 16;14(2):341-50 - PubMed
  3. Angiogenesis. 1999;3(2):147-58 - PubMed
  4. Cancer Res. 1997 Dec 1;57(23):5281-5 - PubMed
  5. Mol Cancer Ther. 2009 Jul;8(7):1779-86 - PubMed
  6. J Urol. 2009 Nov;182(5):2144-9 - PubMed
  7. Endocr Rev. 1997 Feb;18(1):4-25 - PubMed
  8. Int J Biochem Cell Biol. 1999 Sep;31(9):933-40 - PubMed
  9. J Cell Biol. 1987 Jan;104(1):131-9 - PubMed
  10. Lancet. 2012 Aug 18;380(9842):668-79 - PubMed
  11. J Natl Cancer Inst. 1997 Feb 5;89(3):219-27 - PubMed
  12. Eur Urol. 2002 Nov;42(5):464-8 - PubMed
  13. Am J Pathol. 1988 Sep;132(3):543-51 - PubMed
  14. Cancer Res. 2000 Jan 15;60(2):457-66 - PubMed
  15. Pathol Oncol Res. 2011 Mar;17(1):91-101 - PubMed
  16. Cancer Res. 1998 Mar 15;58(6):1298-304 - PubMed
  17. Int J Oncol. 1998 Aug;13(2):355-9 - PubMed
  18. Cancer Metastasis Rev. 1992 Nov;11(3-4):313-24 - PubMed
  19. Cancer Gene Ther. 2000 Dec;7(12):1537-42 - PubMed
  20. J Biol Chem. 2004 Dec 10;279(50):51915-22 - PubMed
  21. Biochim Biophys Acta. 2006 Apr;1765(2):178-88 - PubMed
  22. Am J Pathol. 1992 Jun;140(6):1473-82 - PubMed
  23. Exp Cell Res. 1986 Dec;167(2):376-90 - PubMed
  24. CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29 - PubMed
  25. J Exp Med. 2000 May 15;191(10):1789-98 - PubMed
  26. J Biol Chem. 1989 Jul 5;264(19):11222-7 - PubMed
  27. Blood. 2006 Aug 15;108(4):1280-3 - PubMed
  28. Mol Cell Biol. 1993 Oct;13(10):6336-45 - PubMed
  29. Proc Natl Acad Sci U S A. 2010 Jun 8;107(23):10649-54 - PubMed
  30. Cancer Biol Ther. 2010 Jan;9(2):79-87 - PubMed
  31. Am J Pathol. 1999 Aug;155(2):441-52 - PubMed
  32. J Urol. 1988 Feb;139(2):283-5 - PubMed
  33. Lancet. 2009 Jul 18;374(9685):239-49 - PubMed
  34. Cancer Res. 1987 Aug 1;47(15):4130-3 - PubMed
  35. J Histochem Cytochem. 1993 Oct;41(10):1467-77 - PubMed
  36. Front Biosci. 2007 Jan 01;12:192-213 - PubMed
  37. J Invest Dermatol. 2001 Nov;117(5):1042-9 - PubMed
  38. Biochem Biophys Res Commun. 1994 Sep 15;203(2):857-65 - PubMed
  39. J Cell Biol. 1987 Nov;105(5):2409-15 - PubMed
  40. J Cell Biol. 1990 Aug;111(2):765-72 - PubMed

Publication Types